Clinical significance of hemostasiological screening for thrombophilia in pregnant women with former thrombosis

Introduction. Pregnancy management in post-thrombotic women is challenging, because women with previous episode of venous thromboembolic complications (VTEC) have a 3–4 times higher risk of its exacerbation during than outside of subsequent pregnancies.
Aim: to improve effective prenatal counseling program for women with former venous thrombosis and ischemic stroke to prevent recurrence of arterial and venous complications as well as pregnancy outcomes for mother and fetus.
Materials and Methods. A single-center observational study was conducted involving 50 patients with arterial and venous thrombosis and pregnancy complications in anamnesis and 40 patients with a physiological course of pregnancy. To improve existing methods of thrombosis prevention, risk factors such as gene polymorphisms for plasminogen activator inhibitor-1 (PAI-1), coagulation factor II (prothrombin; F2: Thr165Met), coagulation factor I (fibrinogen; FGB I/D) were investigated as potential new candidates of thrombosis risk markers in pregnant women and puerperas.
Results. In 24 (48 %) of 50 women with former arterial and venous thrombosis and pregnancy complications, were found to develop thromboembolic complications during pregnancy. Risk assessment performed according to the existing thrombosis risk scales, revealed that only 7 (29.2 %) patients were considered as candidates for thromboprophylaxis and received anticoagulant therapy. The remaining 17 women who subsequently developed thrombosis received no anticoagulant therapy. Unfortunately, most women were not tested for thrombophilia despite a history of pregnancy complications (fetal loss, preeclampsia, fetal growth retardation). The hereditary thrombophilia of high thrombogenic risk occurred in 5 (20.8 %) of 24 women with thrombosis during pregnancy (3 – homozygous forms of factor V Leiden mutation, 1 – reduced protein C and 1 – deficiency of protein S and antithrombin). Circulation of various types of antiphospholipid antibodies was found in 13 (54.2 %) of 24 women. Homozygous polymorphisms of the PAI-1 4G/4G (45.8 %) and prothrombin F2 Thr165Met (20.8 %) genes were significantly more common in women with former thrombosis and obstetric complications compared with the control group (p < 0.001 and p = 0.023, respectively; odds ratio = 6.744; 95 % confidence interval = 1.195–38.056).
Conclusion. In all cases examined, 24 women with thrombosis during pregnancy revealed to suffer from hereditary or acquired thrombophilia of high thrombogenic risk. After exclusion of high-risk thrombophilia, a number of gene polymorphisms exist that may be new candidates as a risk factor for thrombosis in pregnant women. More than 50 % of thrombosis cases in our study were associated with the homozygous genotype PAI-1 4G/4G (p < 0.001) and F2 Thr165Met (p < 0.001).

1. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEC). [Rossijskie klinicheskie rekomendacii po diagnostike, lecheniyu i profilaktike venoznyh tromboembolicheskih oslozhnenij (VTEO)]. Flebologiya. 2015;9(4–2):1–52. (In Russ.).

2. Bitsadze V., Khizroeva J., Elalamy I., Makatsariya A. Venous thrombosis risk factors in pregnant women. J Perinat Med. 2020 Oct 26:jpm-2020-0011. https://doi.org/10.1515/jpm-2020-0011. Online ahead of print.

3. Brenner B. Haemostatic changes in pregnancy. Thromb Res. 2004;114(5–6):409–14. https://doi.org/10.1016/j.thromres.2004.08.004.

4. Xiao J., Feng Y., Li X. et al. Expression of ADAMTS13 in normal and abnormal placentae and its potential role in angiogenesis and placenta development. Arterioscler Thromb Vasc Biol. 2017;37(9):1748–56. https://doi.org/10.1161/ATVBAHA.117.309735.

5. Brenner B., Grandone E., Makatsariya A. et al. Approach to the evaluation and treatment of venous thromboembolism in pregnancy. Semin Reprod Med. 2021;39(5–06):186–93. https://doi.org/10.1055/s-0041-1736188.

6. Knight M., Tuffnell D. A view from the UK: The UK and Ireland confidential enquiry into maternal deaths and morbidity. Clin Obstet Gynecol. 2018;61(2):347–58. https://doi.org/10.1097/GRF.0000000000000352.

7. Wik H.S., Jacobsen A.F., Sandvik L., Sandset P.M. Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancyrelated venous thrombosis: a population-based, cross-sectional, casecontrol study. J Thromb Haemost. 2012;10(5):840–7. https://doi.org/10.1111/j.1538-7836.2012.04690.x.

8. Macklon N.S., Greer I.A. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scot Med J. 1996;41(3):83–6. https://doi.org/10.1177/003693309604100305.

9. Cutts B.A., Tran H.A., Merriman E. et al. The utility of the Wells clinical prediction model and ventilation-perfusion scanning for pulmonary embolism diagnosis in pregnancy. Blood Coagul Fibrinolysis. 2014;25(4):375–8. https://doi.org/10.1097/MBC.0000000000000054.

10. Dargaud Y., Rugeri L., Vergnes M.C. et al. A risk score for the management of pregnant womenwith increased risk of venous thromboembolism: a multicentre prospective study. Br J Haematol. 2009;145(6):825–35. https://doi.org/10.1111/j.1365-2141.2009.07698.x.

11. Reducing the risk of venous thromboembolism during pregnancy and the puerperium (Green-top Guideline No. 37a). Royal College of Obstetricians and Gynaecologists, 2015. 40 р. Available at: https://www.rcog.org.uk/media/qejfhcaj/gtg-37a.pdf. [Assessed: 25.09.2022].

12. McColl M., Ramsay J.E., Tait R.C. et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78(4):1183–8.

13. Liu S., Rouleau J., Joseph K.S. et al. Epidemiology of pregnancyassociated venous thromboembolism: a population-based study in Canada. J Obstet Gynaecol Can. 2009;31(7):611–20. https://doi.org/10.1016/S1701-2163(16)34240-2.

14. Sultan A.A., West J., Tata L.J. et al. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol. 2012;156(3):366–73. https://doi.org/10.1111/j.1365-2141.2011.08956.x.

15. James A.H., Jamison M.G., Brancazio L.R., Myers E.R. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311–5. https://doi.org/10.1016/j.ajog.2005.11.008.

16. Clinical guidelines. Venous complications during pregnancy and the postpartum period. Obstetric thromboembolism. [Klinicheskie rekomendacii. Venoznye oslozhneniya vo vremya beremennosti i poslerodovom periode. Akusherskaya tromboemboliya]. Moscow: Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2022. 99 p. (In Russ.). Available at: https://zdrav.khv.gov.ru/sites/files/zdrav/docs/2016/05104b398aef51019755.pdf. [Assessed: 25.09.2022].

17. Ewins K., Ní Ainle F. VTE risk assessment in pregnancy. Res Pract Thromb Haemost. 2019;26;4(2):183–92. https://doi.org/10.1002/rth2.12290.

18. Coutts S.B., Wein T.H., Lindsay M.P. Canadian Stroke Best Practice Recommendations: Secondary prevention of stroke guidelines, update 2014. Int J Stroke. 2015;10(3):282–91. https://doi.org/10.1111/ijs.12439.

19. Lancellotti S., Basso M., Veca V. et al. Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. Intern Emerg Med. 2016;11(7):959–67. https://doi.org/10.1007/s11739-016-1467-x.

20. Setiawan B., Permatadewi C.O., de Samakto B. et al. Von Willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy. Thromb J. 2020;18(1):33. https://doi.org/10.1186/s12959-020-00247-6.

21. Grandone E., Di Micco P.P., Villani M. et al.; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: Data from the RIETE Registry. Thromb Haemost. 2018;118(11):1962–8. https://doi.org/10.1055/s-0038-1673402.

22. Lane D.A., Grant P.J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95(5):1517–32.

23. Colucci G., Tsakiris D.A. Thrombophilia screening revisited: an issue of personalized medicine. J Thromb Thrombolysis. 2020;49(4):618–29. https://doi.org/10.1007/s11239-020-02090-y.

24. Gerhardt A., Scharf R.E., Beckman M.W. et al. Prothrombin and factor V mutations in women with thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342(6):374–80. https://doi.org/10.1056/NEJM200002103420602.

25. Schisterman E.F., Silver R.M., Lesher L.L. et al. Preconception low-dose aspirin and pregnancy outcomes: Results from the EAGeR randomised trial. Lancet. 2014;384(9937):29–36. https://doi.org/10.1016/S0140-6736(14)60157-4.

26. Bell A.D., Roussin A., Cartier R. et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol. 2011;27 Suppl A:S1–59. https://doi.org/10.1016/j.cjca.2010.12.015.

27. Datta P., Rewers-Felkins K., Kallem R.R. et al. Transfer of low dose aspirin into human milk. J Hum Lact. 2017;33(2):296–9. https://doi.org/10.1177/0890334417695207.

28. Chan W.S., Rey E., Kent N.E.; VTE in Pregnancy Guideline Working Group; Society of Obstetricians and Gynecologists of Canada. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can. 2014;36(6):527–53. https://doi.org/10.1016/s1701-2163(15)30569-7.

29. Crowley M.P., Noone C., Higgins J.R., O'Shea S. A multicentre study of thromboprophylaxis in pregnancy. Ir Med J. 2017;110(5):567.

30. Middleton P., Shepherd E., Gomersall J.C. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2021;3(3):CD001689. https://doi.org/10.1002/14651858.CD001689.pub4.

31. Nichols K.M., Henkin S., Creager M.A. Venous thromboembolism associated with pregnancy: JACC Focus Seminar. J Am Coll Cardiol. 2020;76(18):2128–41. https://doi.org/10.1016/j.jacc.2020.06.090.

32. Bates S.M., Greer I.A., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–e736S. https://doi.org/10.1378/chest.11-2300.

33. Sartori M.T., Danesin C., Saggiorato G. et al. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost. 2003;9(4):299–307. https://doi.org/10.1177/107602960300900405.